Piper Jaffray downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Overweight to Neutral with a price target of $158.00 (from $160.00) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

UBS Downgrades Salix Pharmaceuticals (SLXP) to NeutralFebruary 24, 2015 7:22 AM Leerink Swann Downgrades Salix Pharmaceuticals (SLXP) to Market PerformFebruary 23, 2015 7:21 AM Valeant Pharma (VRX) to Acquire Salix Pharma (SLXP) in $14.5B DealFebruary 22, 2015 4:29 PM Valeant Pharma (VRX) Nears Deal for Salix Pharma (SLXP) - CNBC's FaberFebruary 20, 2015 9:46 AM